HYDERABAD, India Dr. Reddy’s Laboratories Ltd. announced its unaudited financial results for the first quarter ended June 30, under International Financial Reporting Standards.
Overall revenues at Rs. 18.2 billion ($381 million) in the first quarter of fiscal year 2010, up 21% from the year-ago period. The growth was largely driven by sumatriptan and by the key markets of North America and India. Excluding revenues from sumatriptan, the growth is at 7%.
EBITDA at Rs. 4.4 billion ($91 million) in first quarter 2010, compared with Rs. 2.3 billion ($48 million), representing a growth of 90%.
Meanwhile, revenues from the global generics business was approximately Rs. 13.0 billion ($273 million), comapred with Rs. 10.3 billion ($215 million) at the same time last year.
During the quarter, the company launched 24 new generic products and filed 22 new generic product registrations.